A real world study of comparison between direct oral anticoagulants (DOACs) and warfarin in atrial fibrillation patients with and without a history of stroke or transient ischemic attack (TIA)

At a glance
Trial Overview
Trial Details
- Other Details
- Related Drugs
Interventions
Results
- Publications
Authors
Trial History
References

Trial Profile

A real world study of comparison between direct oral anticoagulants (DOACs) and warfarin in atrial fibrillation patients with and without a history of stroke or transient ischemic attack (TIA)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
Indications Stroke; Thromboembolism
Focus Adverse reactions; Therapeutic Use

Most Recent Events

06 May 2020 New trial record
10 Apr 2020 Results published in the American Journal of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com